Skip to content Skip to sidebar Skip to footer

Neuren (ASX:NEU) Crashes 10% on EU Setback: Is This a Buying Opportunity?

Neuren Pharmaceuticals: Is the 10% drop a buy signal? Neuren Pharmaceuticals (ASX: NEU) dropped nearly 10% on Tuesday, falling to A$14.63 from a previous close of A$16.25. The sell-off came…

ByUjjwal Maheshwari

Jan 2026

Biotech Stocks

Neuren Pharmaceuticals (ASX:NEU) Surges 6% on US$700m DAYBUE Target: Time to Buy?

DAYBUE royalties could climb fast if US targets land Neuren Pharmaceuticals (ASX: NEU) jumped 6% on Wednesday after its US partner, Acadia Pharmaceuticals, shared big news at the J.P. Morgan…

ByUjjwal Maheshwari

Jan 2026

Biotech Stocks

NeuroScientific (ASX:NSB) Reports 75% Response Rate in Crohn’s Trial: Is This Stem Cell Stock a Buy?

NeuroScientific jumps on early Crohn’s stem cell results NeuroScientific Biopharmaceuticals (ASX: NSB) surged 43% on Tuesday after announcing promising early results from its stem cell program. Three out of four patients…

ByUjjwal Maheshwari

Dec 2025

Biotech Stocks

Cynata Therapeutics Completes Phase 2 Enrollment- Buy Before June or Wait for the Data?

Cynata Therapeutics (ASX: CYP) has completed patient enrollment in its Phase 2 clinical trial of a stem cell treatment called CYP-001 for acute graft versus host disease (aGvHD), a potentially…

ByUjjwal Maheshwari

Dec 2025

Biotech Stocks

Race Oncology Raises $3.2m at 6% Premium: Is RAC Still a Buy After 87% Rally?

Race Oncology’s (ASX: RAC) latest capital raise sends a strong signal. The company secured A$3.2 million from sophisticated investors at $2.83 per share, a 6% premium to its last close.…

ByUjjwal Maheshwari

Dec 2025

Biotech Stocks

Imugene (ASX: IMU) Gets FDA Green Light for Phase 3: Time to Buy the Dip?

Imugene wins FDA support, funding risk remains Imugene (ASX: IMU) received a major regulatory boost this week after the US Food and Drug Administration confirmed support to advance its cancer…

ByUjjwal Maheshwari

Jul 2025

Biotech Stocks Healthcare Stocks Market news

How Trump’s Proposed 200% Tariffs Could Hit CSL (ASX:CSL) and Other Aussie Biotechs

Donald Trump's Tariffs Could Hit CSL and other Aussie Biotechs...it is a reality that is sinking in for many investors. One of the US President's latest proposals — a 200%…

ByUjjwal Maheshwari

the Kick-ass Multipurpose WordPress Theme

Neuren (ASX:NEU) Crashes 10% on EU Setback: Is This a Buying Opportunity?

Neuren Pharmaceuticals (ASX:NEU) Surges 6% on US$700m DAYBUE Target: Time to Buy?

NeuroScientific (ASX:NSB) Reports 75% Response Rate in Crohn’s Trial: Is This Stem Cell Stock a Buy?

Cynata Therapeutics Completes Phase 2 Enrollment- Buy Before June or Wait for the Data?

Race Oncology Raises $3.2m at 6% Premium: Is RAC Still a Buy After 87% Rally?

Imugene (ASX: IMU) Gets FDA Green Light for Phase 3: Time to Buy the Dip?

How Trump’s Proposed 200% Tariffs Could Hit CSL (ASX:CSL) and Other Aussie Biotechs

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Add Your Heading Text Here